Summary Twenty-three patients with advanced NSCLC were treated with high dose chemotherapy using four agents and autologous bone marrow reinfusion. Ten patients received two bolus doses of cyclophosphamide (maximum tolerated total dose 10 G m 2), ifosfamide as a 24 h infusion (11 G m-2) followed by mitomycin C (70 mg m 2) as a subsequent 24 h infusion and mustine as two boluses (total dose 30 mg m 2). Another 13 patients received the same agents except cisplatin was substituted for cyclophosphamide, two doses (total dose 100 mg m 2) being given in a 24 h period. The 
Single agent tumour responses rates in advanced non small cell lung cancer (NSCLC) are of the order of 20%, even with the most active agents -ifosfamide, cisplatin, mitomycin C. Complete responses are rare (Bakowski & Crouch, 1983) . Other alkylating agents -mustine and cyclophosphamide are also active and high dose cyclophosphamide has an enhanced response even in patients refractory to standard doses (Selawry, 1982; Thatcher et al., 1988; Slease et al., 1988; Frei et al., 1989) .
Alkylating agents and cisplatin exhibit steep dose response curves in experimental systems, and clinical data indicate a similar relationship (Frei, 1979; Frei & Canellos, 1980) . There is further evidence both in vitro and in vivo that non-cross resistance occurs between alkylating agents (Schabel et al., 1978; Teicher et al., 1986) . High dose combination alkylating agent therapy is therefore attractive, particularly as the major dose limiting toxicity of these agents is myelosuppression which can be ameliorated by autologous bone marrow re-infusion (ABMR).
Materials and methods

Patients
Twenty-three patients with histologically proven NSCLC were entered into the study from March 1986 to March 1988. There were seven female and 16 male patients with a median age of 40 years. All patients had Stage IlIb disease or greater (Mountain, 1986) . Ipsilateral supraclavicular (SCF) lymphadenopathy was present in four patients, contralateral SCF nodes in two patients and pleural effusions in seven patients. All patients were unsuitable for radical radiotherapy or resection, the patient characteristics are described in Table I . Patient consent was obtained after explanation of the high dose regimen, supportive measures and toxicity likely to be encountered. All patients had to have pre-treatment Kamofsky scores of 50 or more, adequate pre-treatment bone marrow function (WBC> 3 x I09 1, platelet count> 100x 109 1) and normal bone marrow aspirate and trephine. In addition patients older than 55 years of age, those with other medical conditions which would make the high dose treatment unduly dangerous, and those with cerebral metastases were excluded from the study. Twenty-two patients had received no previous treatment, the other patient had developed recurrence following lobectomy.
Pre-treatment evaluation Patients were assessed by routine history, clinical examination, routine blood counts, hepatic, renal biochemistry and chest radiography. Pre-treatment bone marrow aspirate examination and CT scanning of the thorax, brain and abdomen were performed.
Bone marrow harvest and chemotherapy regimen Before chemotherapy a subclavian vein central catheter was inserted followed by bone marrow harvest. Partial anticoagulation was achieved with 3-5,000 units of preservative free heparin. Bone marrow aspirates from the posterior iliac crest and sternum were stored at 4°C in (75 ml) acid citrate dextrose (Thatcher et al., 1989 Chemotherapy was given as in the diagram. For ifosfamide and mitomycin C a loading dose of each drug (25-30% of the total dose) was given over the first hour of the 24 h infusion. In the first ten patients cyclophosphamide was given as a bolus at 8 and 16 h after the start of the ifosfamide and mesna (24 h) infusion. Cisplatin with mannitol diuresis and electrolytes were substituted for cyclophosphamide in the other 13 patients after noting the low CR rate with the cyclophosphamide regimen.
All patients were well hydrated before and during chemotherapy with at least 3 litres m-2 of normal saline and dextrose-saline given intravenously over a period of 6 h. Further fluid was given as required to obtain a satisfactory urine Supportive care output of 150 ml per hour. The drug dosages were escalated and the total dosages delivered are shown in Leff et al. (1986) . The Karnofsky score and MRC respiratory score, a measure of breathlessness was assessed before and at regular intervals after treatment (MRC Lung Cancer Working Party, 1979) .
Results
Response and survival Seventeen out of the total of 23 patients responded to treatment 74% (95% confidence limits 52-90%). Of these five 22% (95% confidence limits 7-44%) were complete responders as assessed by repeat CT scan. The median survival of the total group of patients was 6 months range < 1-20.5 + months, see Table I. Seven of the ten patients responded with the quadruple regime which included cyclophosphamide (regimen A) with two complete responders. However, no patient in this group survived longer than 18 months (Table I) . Responses occurred in the primary lung tumour, mediastinal and peripheral nodes, although bone and the pulmonary metastases also responded. Median duration of response was 12 weeks (range 7-31 weeks). With the cisplatin combination (regimen B), responses were mainly in the primary tumour and mediastinum, but also in bone and nodal metastases. Median duration of response was 32 weeks (range 7-80 + weeks). Three patients (all in the regimen B group) are still alive, two who continue in complete response and one in PR, see Table I .
There was no statistically significant difference in survival between the two treatment regimens (P = 0.62). The median survival with the cyclophosphamide, regimen (A) was 20 weeks (range 2-78) and with the cisplatin regimen (B) 30 weeks (range 2-82+).
All patients have been evaluated for toxicity. The haematological toxicity and blood count recovery times are shown in Table II . There was no significant difference between the two regimens, nor was there any obvious difference in the requirement for supportive care. The vast majority of patients were able to be discharged 3 to 4 weeks after start of treatment. There was considerable gastrointestinal disturbance in the first 2 weeks of treatment (Table III) . The main problem was stomatisis, particularly in the second and third week, and this was associated with altered taste sensation for up to 2 months after treatment. Despite the considerable non-haematological toxicity the patients' Karnofsky performance scores remained fairly stable and breathlessness improved particularly with the cisplatin regimen (Tables IV  and V) .
Two patients in the cyclophosphamide group and one patient in the cisplatin group died 2 weeks after starting treatment. The latter patient had renal failure and tumour involvement of the kidneys at autopsy. In the cyclophosphamide group one patient at post-mortem had a subdural haematoma, intracerebral haemorrhage with petechial haemorrhages in the stomach, duodenum and small bowel in the absence of pancytopenia or any clotting defect. The second patient developed increasing dyspnoea but at post mortem 4,5* 1 3 2 1 3 3 3 5 7 7 3 5 -2 -3 -3 -3 1,2 9 5 8 10 7 7 7 5 3 3 Grade 1, 2 climb hills, stairs, walk any distance on the flat at normal pace, without dyspnoea; Grade 3, 4 walks more than 100 yards at own speed without dyspnoea, dyspnoea on walking 100 yards or less; Grade 5 dyspnoea on mild exertion, e.g. undressing (dying patients included).* (MRC Lung Cancer Working Party -1979).
there was no bronchopneumonia, but tumour was involving the oesophagus, pericardium, mediastinum, left hilum and left lower lobe.
Discussion
The maximum tolerated doses (MTD) identified in the present study were as follows. Cyclophosphamide 5 G m-2 given twice (i.e. 10 G total) in a 24 h period, ifosfamide 11 G m-2 given as an infusion over 24 h, mustine 30 mg m-2 total again given on two occasions within a 24 h period and mitomycin C as a 24 h infusion of 70 mg m-2. The cisplatin (total dose of 100 mg m-2) was given on two occasions within a 24 h period with fluid diuresis and close monitoring of the urine output. These values can be compared with previous reports of MTDs for mustine of 30 mg m2, higher doses were said to be associated with neurotoxicity and cardiotoxicity and mitomycin C 60 mg m-2 higher doses being associated with veno-occlusive disease and haemorrhagic colitis although toxicity was somewhat reduced by infusions. Cyclophosphamide at high dose (> 160 mg kg-') has been associated with haemorrhagic myocarditis when used in combination with other agents (Postmus & de Vries, 1984) . Data on ifosfamide are available from our previous study in melanoma in which two doses, each of 4 G m-2 in a 24h period could be safely administered (Thatcher et al., 1989) . Recently other studies have examined cisplatin in combination with cyclophosphamide and BCNU and have identified MTDs of 5.6 G m-2 for cyclophosphamide and 165 mg m-2 for cisplatin which are approximately 6-fold and 1.5-fold greater than standard doses (Peters et al., 1986) .
Non small cell lung cancer has been examined previously in five patients who were part of larger studies including a variety of solid tumours, investigating single agent high dose chemotherapy with ABMR. In these five patients there were two responses and in another eight patients treated with high dose combination chemotherapy, there were six partial remissions (Cheson et al., 1989) . The agents used in these studies would not be considered to be particularly effective in NSCLC. The only study addressing the subject in some detail was of 15 patients with stage IV NSCLC treated with cyclophosphamide (7.5 G m-2 over 3 days) with thiotepa escalated from 1.8 mg kg-' to 6.0mg kg-' also over 3 days. A further seven patients received oral melphalan, 0.75 mg kg-' to 2.5mg kg-' over 3 days (Williams et al., 1989) . Of the 13 evaluable patients in this study, there were no complete responders and seven (47%) obtained a partial response with a median duration of 3 months. There was significant nonhaematological toxicity involving the GI tract, haemorrhagic cysitits and cardiomyopathy.
The current study of 23 patients demonstrated that higher doses of the more active agents in NSCLC can be given without overwhelming non-haematological toxicity. In particular there was no evidence of veno-occlusive disease of the liver nor of colitis, encephalopathy, cardiomyopathy. The avoidance of these non-haematological dose limiting toxicities is clearly due to multiple factors, for example a reasonably good performance status, the lack of abnormal liver function, renal function before treatment, the use of infusion therapy and possibly the support with selenium and other trace elements could have prevented the colitis and haemorrhagic myocarditis (Thatcher et al., 1989) . The marrow recovery within 3 weeks despite these high doses is likely to be due to the marrow rescue programme. There was no evidence that the higher doses were associated with longer recovery times or greater myelosuppression suggesting that bone marrow support did contribute to recovery from myelosuppression. There was no evidence of refractory thrombocytopaenia although this has been reported previously (Peters et al., 1986) .
Although a very gratifying response rate with five complete responders was observed, as in other studies of refractory tumours the overall median duration of response was short. The study did demonstrate that higher than expected responses could be obtained albeit in a young and fitter population compared with most NSCLC patients, but with only a minority surviving more than 1 year. However, there were three deaths which could be ascribed to treatment which is similar to other reports of high dose combination therapy (Peters et al., 1986) .
As suggested for breast cancer it could be possible to consider an intensive approach after remission has been obtained with combinations of the most active agents in NSCLC e.g. ifosfamide, cisplatin, mitomycin C. The lack of substantial non-haematological toxicity suggests that the approach might be feasible in a selected group of patients with advanced NSCLC. The requirement for ABMR may also be offset by the use of haematological growth factors (Bronchud et al., 1987) . Nevertheless the single high dose strategy described in the current report had no survival advantage over conventional dosages of the same agents previously used in metastatic NSCLC.
